Share this article
MONTRÉAL, Jan. 21, 2021 /PRNewswire/ -
Eli, a company enabling women to own their fertility and health decisions with a novel hormone tracking technology, today announced its $1.5 million USD seed round co-led by Vectr Ventures and 2048 Ventures. The round closed in December 2020 with the participation of Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and serial entrepreneur Steven Arless, who also joined the board.The round brings the company s total funding since its creation in mid-2019 to $2.1 million USD. This amount includes a previous investment from Techstars and Real Ventures via Techstars Montréal AI. Hormones are core to women s fertility and general health, yet they remain a black box. We are unlocking that box and empowering women to have access to their own hormone data daily,
Eli raises $1.9 million CAD in seed funding to develop at-home hormone monitoring tech
Eli Science Inc. has raised a $1.9 million CAD ($1.5 million USD) seed round to target the historically underserved women’s healthtech market via its saliva-based daily hormone tracking technology.
The round, which was co-led by Hong Kong’s Vectr Ventures and 2048 Ventures, closed in late December 2020. Other investors included Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and Steven Arless, who joined Eli Health’s board of directors. To date, the company has raised a total of $2.1 million USD, including prior investments from Techstars and Real Ventures through Techstars Montreal AI accelerator.